Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris

Am J Cardiol. 1999 Apr 1;83(7):1120-4, A9. doi: 10.1016/s0002-9149(99)00025-9.

Abstract

After 2 weeks of nicorandil therapy, time to ischemia on stress testing was significantly less than on day 1 and not different from placebo. These data are consistent with attenuation of the anti-ischemic effects of this drug and suggest that the potassium channel-opening properties do not compensate for development of attenuation to the nitrate component of nicorandil.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Adult
  • Aged
  • Angina Pectoris / drug therapy*
  • Angina Pectoris / physiopathology
  • Blood Pressure / drug effects
  • Calcium Channel Blockers / therapeutic use
  • Cross-Over Studies
  • Diltiazem / therapeutic use
  • Double-Blind Method
  • Electrocardiography
  • Exercise Test
  • Female
  • Heart Rate / drug effects
  • Humans
  • Male
  • Middle Aged
  • Myocardial Ischemia / prevention & control
  • Nicorandil / administration & dosage
  • Nicorandil / therapeutic use*
  • Time Factors
  • Verapamil / therapeutic use

Substances

  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers
  • Nicorandil
  • Verapamil
  • Diltiazem